| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 3,885,795 | 3,873,993 | 3,619,108 | 3,266,846 |
| Cost of revenue | 704,297 | 757,193 | 855,140 | 807,672 |
| Gross profit | 3,181,498 | 3,116,800 | 2,763,968 | 2,459,174 |
| Selling, general and administrative expenses | 2,304,881 | 2,138,692 | 2,381,734 | 2,248,864 |
| Research and development expenses | 602,798 | 696,163 | 551,216 | 517,982 |
| Total operating expenses | 2,907,679 | 2,834,855 | 2,932,950 | 2,766,846 |
| Profit (loss) from operations | 273,819 | 281,945 | -168,982 | -307,672 |
| Other income/(expense) note 3 | 106,599 | 66,671 | 65,512 | 36,314 |
| Interest expense | 860,419 | 850,254 | - | - |
| Accretion and amortization expenses | -202,141 | -153,572 | -291,128 | -339,888 |
| Gain (loss) upon convertible promissory notes conversion and redemption note 9 | - | 8,433 | -17,357 | -4,690 |
| Interest expense | - | - | 849,538 | 752,075 |
| Change in fair value of derivative liabilities note 8 | -8,771 | -25,200 | 32,339 | -193,757 |
| Net loss before income taxes | -690,913 | -671,977 | -1,229,154 | -1,561,768 |
| Income taxes note 3 | - | 0 | - | - |
| Net loss before dividends | -690,913 | -671,977 | -1,229,154 | -1,561,768 |
| Preferred stock dividends | 81,410 | 82,316 | 89,392 | 91,261 |
| Deemed dividends note 9 | - | 0 | - | - |
| Net loss attributable to common stocklholders | -772,323 | -754,293 | -1,318,546 | -1,653,029 |
| Translation adjustment | 9,286 | -36,169 | 76,680 | -129,376 |
| Comprehensive loss | -763,037 | -790,462 | -1,241,866 | -1,782,405 |
| Loss per share, basic | -0.029 | -0.029 | -0.054 | -0.073 |
| Loss per share, diluted | -0.029 | -0.029 | -0.054 | -0.073 |
| Weighted average number of common shares outstanding - basic | 26,767,370 | 26,284,734 | 24,232,369 | 22,493,626 |
| Weighted average number of common shares outstanding - diluted | 26,767,370 | 26,284,734 | 24,232,369 | 22,493,626 |
BIOTRICITY INC. (BTCY)
BIOTRICITY INC. (BTCY)